NASDAQ:OPRX - OptimizeRx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.48 +0.85 (+5.44 %) (As of 05/20/2019 04:00 PM ET)Previous Close$15.63Today's Range$15.04 - $16.7552-Week Range$7.25 - $18.39Volume149,900 shsAverage Volume54,251 shsMarket Capitalization$199.33 millionP/E Ratio329.20Dividend YieldN/ABeta0.94 ProfileAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan. Receive OPRX News and Ratings via Email Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:OPRX Previous Symbol CUSIPN/A CIKN/A Webwww.optimizerx.com Phone248-651-6568Debt Debt-to-Equity Ratio0.03 Current Ratio4.02 Quick Ratio4.02Price-To-Earnings Trailing P/E Ratio329.20 Forward P/E Ratio86.74 P/E Growth1.67 Sales & Book Value Annual Sales$21.21 million Price / Sales9.40 Cash Flow$0.0755 per share Price / Cash Flow218.35 Book Value$1.61 per share Price / Book10.24Profitability EPS (Most Recent Fiscal Year)$0.05 Net Income$230,000.00 Net Margins1.90% Return on Equity3.25% Return on Assets2.60%Miscellaneous Employees37 Outstanding Shares12,095,000Market Cap$199.33 million Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions What is OptimizeRx's stock symbol? OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX." How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings results on Monday, November, 5th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.01. The company earned $5.42 million during the quarter, compared to analyst estimates of $5.28 million. OptimizeRx had a return on equity of 3.25% and a net margin of 1.90%. View OptimizeRx's Earnings History. When is OptimizeRx's next earnings date? OptimizeRx is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for OptimizeRx. What price target have analysts set for OPRX? 4 Wall Street analysts have issued 12-month price objectives for OptimizeRx's stock. Their predictions range from $17.00 to $25.00. On average, they anticipate OptimizeRx's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View Analyst Price Targets for OptimizeRx. What is the consensus analysts' recommendation for OptimizeRx? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptimizeRx. Has OptimizeRx been receiving favorable news coverage? Media stories about OPRX stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OptimizeRx earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the next several days. Who are some of OptimizeRx's key competitors? Some companies that are related to OptimizeRx include Stamps.com (STMP), Cass Information Systems (CASS), COMSCORE (SCOR), Uxin (UXIN), i3 Verticals (IIIV), Gravity (GRVY), TechTarget (TTGT), B. Riley Financial (RILY), Resources Connection (RECN), International Money Express (IMXI), Exela Technologies (XELA), NEWTEK Business Services (NEWT), 3Pea International (PAYS), Limelight Networks (LLNW) and Rimini Street (RMNI). What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include Micron Technology (MU), Amgen (AMGN), Inpixon (INPX), Conatus Pharmaceuticals (CNAT), Exelixis (EXEL), Harvard Bioscience (HBIO), Intel (INTC), Nuance Communications (NUAN), NVIDIA (NVDA) and Sangamo Therapeutics (SGMO). Who are OptimizeRx's key executives? OptimizeRx's management team includes the folowing people: Mr. William J. Febbo, CEO & Director (Age 50)Ms. Miriam J. Paramore, Pres (Age 56)Mr. Douglas P. Baker, Chief Financial Officer (Age 62)Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)Mr. James Brooks, Consultant (Age 50) Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by many different of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (7.89%), Wasatch Advisors Inc. (2.70%), Perkins Capital Management Inc. (1.77%), 1492 Capital Management LLC (1.00%), Timpani Capital Management LLC (0.87%) and Blair William & Co. IL (0.53%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Institutional Ownership Trends for OptimizeRx. Which institutional investors are selling OptimizeRx stock? OPRX stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Alambic Investment Management L.P., Park West Asset Management LLC, 1492 Capital Management LLC, Timpani Capital Management LLC, Acadian Asset Management LLC and Perkins Capital Management Inc.. Company insiders that have sold OptimizeRx company stock in the last year include Awm Investment Company, Inc and Douglas P Baker. View Insider Buying and Selling for OptimizeRx. Which institutional investors are buying OptimizeRx stock? OPRX stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Marshall Wace LLP, Granite Investment Partners LLC, Tibra Equities Europe Ltd, BlackRock Inc., JPMorgan Chase & Co., Westwood Management Corp IL and Citigroup Inc.. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Miriam J Paramore, Patrick D Spangler and William J Febbo. View Insider Buying and Selling for OptimizeRx. How do I buy shares of OptimizeRx? Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OptimizeRx's stock price today? One share of OPRX stock can currently be purchased for approximately $16.48. How big of a company is OptimizeRx? OptimizeRx has a market capitalization of $199.33 million and generates $21.21 million in revenue each year. The company earns $230,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. OptimizeRx employs 37 workers across the globe. What is OptimizeRx's official website? The official website for OptimizeRx is http://www.optimizerx.com. How can I contact OptimizeRx? OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected] MarketBeat Community Rating for OptimizeRx (NASDAQ OPRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 45 (Vote Outperform)Underperform Votes: 52 (Vote Underperform)Total Votes: 97MarketBeat's community ratings are surveys of what our community members think about OptimizeRx and other stocks. Vote "Outperform" if you believe OPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Determine Your Level of Risk Tolerance Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.